Nov 11, 2026 · 1h 18m
Ro bets healthcare’s future on patient demand and software
Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
The conversation tests whether technology can shift healthcare toward measurable healthy years, consumer choice, and broadly affordable personalized care.
- 1Healthcare spending should be judged by healthy years created, not by its share of GDP alone.
- 2Ro’s turnaround came from sharper focus, stronger cultural standards, and sequential execution rather than continued organizational expansion.
- 3AI, software, and consumer demand could make concierge-level preventive care widely accessible while challenging healthcare’s traditional incentives.
Don't miss
Zach Reitano recounts his father’s heart attack and the final request that taught him never to leave love unspoken.
The brief
Zach Reitano argues that healthcare’s value should be measured by healthy years created, not by whether its share of GDP looks too large. The central customer, he says, should be the patient.
Ro’s GLP-1 business illustrates that thesis: direct patient demand can improve price, convenience, access, and treatment choice when insurers and employers no longer define the market.
The company’s turnaround followed a refounding around focus, talent density, short roadmaps, and a strong-attract, strong-repel culture—an operating reset after becoming overbuilt and slow-growing.
Reitano sees three healthcare tailwinds: measurable biology, AI-enabled specialist expertise, and more powerful treatments. Together, they could make concierge-level care affordable through consumer software.
The conversation ends personally, with Reitano recalling his father’s final lesson: never leave love unspoken. It gives the healthcare argument a human measure beyond growth or efficiency.
What was said on this episode
27 statements · 21 positive · 4 negative · 2 neutral
- Zach Reitanoon U.S. healthcare systemNegative6:17
Healthcare misaligns incentives because patients are not usually treated as customers
“the patient is not the customer. That's the problem that we're trying to solve at Roe.”
Listen at 6:17
- Zach Reitanoon LASIK eye surgeryPositive6:57
Cash-pay LASIK has lower costs, higher quality, and greater convenience
“You look at LASIK eye surgery, cost comes down, quality improves, convenience improves.”
Listen at 6:57
- Zach Reitanoon branded drugsNegative7:43
Branded drug prices typically rise 6% to 8% annually
“normally branded drugs, every year, systematically, they go up 6%, 7%, 8% year over year over year.”
Listen at 7:43
- Zach Reitanoon healthcare softwarePositive8:16
Software can replace historical PBM functions
“software can do exactly what they would have done historically.”
Listen at 8:16
Direct-to-consumer GLP-1 access can lower prices while increasing drugmaker revenue
“Prices go from $1,300 to $149. and the people making the drugs are making more money.”
Listen at 8:30
- Zach Reitanoon patient spending aggregationPositive10:34
Aggregating patient spending could make healthcare more patient-centered
“if we can aggregate patient spend, I think we can bend the healthcare system to the will of patients.”
Listen at 10:34
- Zach Reitanoon Ro GLP-1 businessPositive11:01
GLP-1s are Ro’s fastest-growing business segment
“the fastest growing part of the business is GLP-1s.”
Listen at 11:01
GLP-1 drugs have gained approvals across multiple chronic conditions
“they were approved for diabetes, then they're approved for obesity and overweight, then they're approved for heart disease, then they're approved for sick apnea and liver disease and kidney disease.”
Listen at 11:24
- Zach Reitanoon Ro GLP-1 enrollmentPositive12:23
Ro likely enrolls several times more GLP-1 patients daily than competitors
“we're probably signing up two, three, four, five times as many patients every single day as our competition.”
Listen at 12:23
- Zach Reitanoon Ro multi-month subscriptionsPositive13:09
Ro’s multi-month subscriptions can save patients $600 to $1,800 annually
“we can actually save patients $600 to $1,800 a year.”
Listen at 13:09
- Zach Reitanoon business differentiationNeutral13:22
Continued innovation is the only durable source of differentiation
“the only, only, only source of differentiation is continued innovation.”
Listen at 13:22
Ro is a vertically integrated care and treatment distribution platform
“a world-class care and treatment distribution platform that is all vertically integrated, custom-built software”
Listen at 14:22
GLP-1 inventors should capture more margin than access providers
“the inventors of GLP-1s should grab more margin than the people who scale access to debt.”
Listen at 14:58
Ro is executing better than competitors on the GLP-1 growth wave
“we're doing it better than anyone else.”
Listen at 38:59
- Zach Reitanoon long-term company roadmapsNegative42:22
Companies should eliminate long-term roadmaps
“I would advocate this for every company.”
Listen at 42:22
- Zach Reitanoon long-term roadmapsNegative42:43
Long-term roadmaps are wasteful in rapidly changing industries
“Spending a lot of time on long-term roadmaps is like printing out MapQuest instead of using Google Maps. It is false precision. It's a giant waste of time.”
Listen at 42:43
- Zach Reitanoon chronic diseaseNeutral47:17
Chronic disease risk depends partly on cumulative exposure over time
“a lot of chronic disease are area under the curve problems.”
Listen at 47:17
- Zach Reitanoon personal treatment selectionPositive47:43
Patients should work with providers to choose treatment combinations
“you're going to have to ideally, you work with a provider to understand what combination of treatments might be right for you.”
Listen at 47:43
- Zach Reitanoon Zach’s cardiovascular medicationsPositive51:07
Zach considers his cardiovascular medications safe with favorable side effects
“I take these medications, they're remarkably safe. The side effect profile for me is incredibly favorable.”
Listen at 51:07
Direct sales reduced Repatha’s monthly price from $600 to $200
“What happened when it went direct? Went from $600 a month to $200. Went down 60, 70%”
Listen at 51:30
AI performs especially well with structured data, verifiable rewards, and tight feedback loops
“AI is really, really good, as we all know, it's where there's a ton of structured data, when there's a verifiable reward, and there's a really tight feedback loop.”
Listen at 51:49
People with faulty PCSK9 genes have 85% to 90% lower heart-disease risk
“they have a 85 to 90% risk reduction of heart disease”
Listen at 52:37
Early oral PCSK9 treatment might largely prevent heart disease deaths
“if taken early enough, might largely prevent and eliminate the leading cause of death in the U.S.”
Listen at 53:11
- Zach Reitanoon life expectancyPositive53:57
Healthcare may be approaching another major life-expectancy improvement
“I think we're on the cusp of another shift of that zero to 1800 where life expectancy was 30.”
Listen at 53:57
Ro publishes data on patient outcomes and side-effect response times
“We've published data on the outcomes. We publish data on our side effect response times.”
Listen at 1:02:13
- Zach Reitanoon Ro side-effect supportPositive1:02:30
Ro responds to reported side effects within 30 minutes around the clock
“we have a 24-7, sub-30-minute response time for your side effect.”
Listen at 1:02:30
Serena Williams is a Ro ambassador for GLP-1s
“She's an ambassador for a row body for Jilkey Ones.”
Listen at 1:03:44
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.